Suppr超能文献

质子束疗法作为重度预处理视网膜母细胞瘤眼挽救治疗的可行性

Feasibility of Proton Beam Therapy as a Rescue Therapy in Heavily Pre-Treated Retinoblastoma Eyes.

作者信息

Biewald Eva, Kiefer Tobias, Geismar Dirk, Schlüter Sabrina, Manthey Anke, Westekemper Henrike, Wulff Jörg, Timmermann Beate, Ketteler Petra, Schönberger Stefan, Metz Klaus A, Ting Saskia, Göricke Sophia, Bechrakis Nikolaos E, Bornfeld Norbert

机构信息

Department of Ophthalmology, University Hospital Essen, University Duisburg Essen, 45122 Essen, Germany.

Department of Particle Therapy, West German Proton Therapy Centre Essen (WPE), University Hospital Essen, German Cancer Consortium (DKTK), 45122 Essen, Germany.

出版信息

Cancers (Basel). 2021 Apr 13;13(8):1862. doi: 10.3390/cancers13081862.

Abstract

Despite the increased risk of subsequent primary tumors (SPTs) external beam radiation (EBRT) may be the only therapeutic option to preserve a retinoblastoma eye. Due to their physical properties, proton beam therapy (PBT) offers the possibility to use the effectiveness of EBRT in tumor treatment and to decisively reduce the treatment-related morbidity. We report our experiences of PBT as rescue therapy in a retrospectively studied cohort of 15 advanced retinoblastoma eyes as final option for eye-preserving therapy. The average age at the initiation of PBT was 35 (14-97) months, mean follow-up was 22 (2-46) months. Prior to PBT, all eyes were treated with systemic chemotherapy and a mean number of 7.1 additional treatments. Indication for PBT was non-feasibility of intra-arterial chemotherapy (IAC) in 10 eyes, tumor recurrence after IAC in another 3 eyes and diffuse infiltrating retinoblastoma in 2 eyes. Six eyes (40%) were enucleated after a mean time interval of 4.8 (1-8) months. Cataract formation was the most common complication affecting 44.4% of the preserved eyes, yet 77.8% achieved a visual acuity of >20/200. Two of the 15 children treated developed metastatic disease during follow-up, resulting in a 13.3% metastasis rate. PBT is a useful treatment modality as a rescue therapy in retinoblastoma eyes with an eye-preserving rate of 60%. As patients are at lifetime risk of SPTs consistent monitoring is mandatory.

摘要

尽管后续原发性肿瘤(SPT)的风险增加,但外照射放疗(EBRT)可能是保留视网膜母细胞瘤患眼的唯一治疗选择。由于其物理特性,质子束治疗(PBT)提供了利用EBRT在肿瘤治疗中的有效性并决定性降低治疗相关发病率的可能性。我们报告了在一组15例晚期视网膜母细胞瘤患眼的回顾性研究队列中,将PBT作为挽救治疗的经验,这是保眼治疗的最终选择。开始PBT治疗时的平均年龄为35(14 - 97)个月,平均随访时间为22(2 - 46)个月。在进行PBT之前,所有患眼均接受了全身化疗,平均额外接受了7.1次治疗。PBT的适应证为10例患眼无法进行动脉内化疗(IAC),另外3例患眼在IAC后肿瘤复发,2例患眼为弥漫浸润性视网膜母细胞瘤。6例患眼(40%)在平均4.8(1 - 8)个月的时间间隔后被摘除眼球。白内障形成是最常见的并发症,影响了44.4%的保留眼球,但77.8%的患眼视力达到>20/200。15例接受治疗的儿童中有2例在随访期间发生转移性疾病,转移率为13.3%。PBT作为视网膜母细胞瘤患眼的挽救治疗是一种有用的治疗方式,保眼率为60%。由于患者终生有患SPT的风险,因此必须进行持续监测。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/656d/8069965/f79a2937ca7f/cancers-13-01862-g001.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验